Either party may elect not to renew the U.S. Renewal Term and/or the EU Renewal Term by providing the requisite prior notice to the other party, with the initial terms automatically renewing for successive two-year terms, unless either party gives notice pursuant to the Renaissance Agreement. Either party may terminate the Renaissance Agreement (1) for uncured material breach of the other party, (2) upon notice for insolvency-related events of the other party that are not discharged within a defined time period, (3) on a product-by-product basis if the manufacture, distribution or sale would materially contravene any applicable law, (4) by providing the requisite notice if (a) the authorization and approval to distribute or sell Renaissance Product in the U.S. is not granted on or before a specified date, (b) the authorization and approval representing more than a certain number of units of Renaissance Product sold in the U.S. during the last calendar year is withdrawn by the FDA, or (c) the Company decided in its sole discretion to cease commercializing the Renaissance Product in the U.S., (5) in the case of a force majeure event that continues for six months or more, or (6) a violation by the other party of trade control or anti-corruption laws.

In-Licensing and Supply - Additional Information (Detail) € in Millions	1 Months Ended			3 Months Ended			6 Months Ended
	Dec. 31, 2024 USD ($)	Dec. 31, 2024 EUR (€)	Jun. 30, 2018 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Sep. 30, 2022 USD ($)	Jun. 30, 2025 USD ($)	Jun. 30, 2024 USD ($)	Oct. 31, 2024 USD ($)	Sep. 30, 2024 USD ($)	Aug. 31, 2024 USD ($)
In Licensing and Supply [Line Items]
Capitalized milestone payments	$ 7,500,000			$ 13,360,000			$ 13,360,000
Intangible assets, net	7,371,000			12,972,000			$ 12,972,000
Ompi Supply Agreement [Member]
In Licensing and Supply [Line Items]
Upfront payment	$ 3,200,000	€ 3.0
Supply Agreement Expiration Date							Dec. 31, 2035
Agreement Termination, Due To Material Breach							90 days
Aegis Therapeutics Agreement
In Licensing and Supply [Line Items]
Upfront License Fees			$ 50,000,000
Aggregate milestone payments upon achievement of certain sales milestones							$ 20,000,000
Regulatory milestone						$ 1,000,000	500,000
Milestone payment due							$ 2,000,000
Capitalized milestone payments										$ 5,000,000	$ 2,500,000
Notice Period Description							The Company may terminate the Aegis Agreement with 30 days written notice or either party may terminate the Aegis Agreement for certain breaches of the Aegis Agreement. Unless terminated earlier by either or both parties, the term of the Aegis Agreement will continue until the final expiration of all royalty obligations under the Aegis Agreement.
Legal Patent Fees				0	$ 0		$ 0	$ 0
Supply Agreement Expense				$ 0	$ 0		$ 0	$ 0
Aegis Therapeutics Agreement \| First Commercial Sale Of Neffy
In Licensing and Supply [Line Items]
Capitalized milestone payments									$ 5,000,000	5,000,000
Aegis Therapeutics Agreement \| Intellectual Property
In Licensing and Supply [Line Items]
Estimated Life of Finite Lived Intangible Assets				14 years 6 months			14 years 6 months
Aegis Therapeutics Agreement \| Intangible Assets
In Licensing and Supply [Line Items]
Capitalized milestone payments										7,500,000
Aegis Therapeutics Agreement \| New Drug Application [Member]
In Licensing and Supply [Line Items]
Capitalized milestone payments										$ 2,500,000
Renaissance Agreement
In Licensing and Supply [Line Items]
Contract Termination Claims, Description							Either party may elect not to renew the U.S. Renewal Term and/or the EU Renewal Term by providing the requisite prior notice to the other party, with the initial terms automatically renewing for successive two-year terms, unless either party gives notice pursuant to the Renaissance Agreement. Either party may terminate the Renaissance Agreement (1) for uncured material breach of the other party, (2) upon notice for insolvency-related events of the other party that are not discharged within a defined time period, (3) on a product-by-product basis if the manufacture, distribution or sale would materially contravene any applicable law, (4) by providing the requisite notice if (a) the authorization and approval to distribute or sell Renaissance Product in the U.S. is not granted on or before a specified date, (b) the authorization and approval representing more than a certain number of units of Renaissance Product sold in the U.S. during the last calendar year is withdrawn by the FDA, or (c) the Company decided in its sole discretion to cease commercializing the Renaissance Product in the U.S., (5) in the case of a force majeure event that continues for six months or more, or (6) a violation by the other party of trade control or anti-corruption laws.